Hub : Traits

Conditioned locomotion

Tags: Behavior · Locomotion

Project: p50_paul_meyer_2020

1 loci · 1 genes with independent associations · 2 total associated genes

Significant Loci

#	Chr	Start pos	End pos	# assoc genes	# joint models	Best TWAS P	Best GWAS P	Cond GWAS P	Joint genes
1	1	187833756	189718769	2	1	7.84e-08	1.99e-09	1.56e-03	Adam12

Pleiotropic Associations

Trait	Chi2 ratio	# genes+	# genes++	% genes++	Corr	Corr P	Genes
BMI with tail	2.31	1	0	0	0	1.00e+00	Uros
Epididymis fat weight	3.06	1	0	0	0	1.00e+00	Uros
Tail length	2.51	1	0	0	0	1.00e+00	Uros
Length without tail	3.51	1	0	0	0	1.00e+00	Uros
Retroperitoneal fat weight	2.16	1	0	0	0	1.00e+00	Uros
Tibia length	3.37	1	0	0	0	1.00e+00	Uros
Locomotor activity	4.34	1	0	0	0	1.00e+00	Uros
Locomotor testing distance	4.62	1	0	0	0	1.00e+00	Uros
Locomotor testing rearing	4.87	2	0	0	0.99	5.91e-03	Uros Adam12
Saline control response	7.88	1	0	0	0	1.00e+00	Uros
Conditioned reinforcement - actives	22.49	2	0	0	1	6.19e-04	Uros Adam12
Conditioned reinforcement - inactives	6.79	2	0	0	0	1.00e+00	Uros Adam12
Intermittent access day 1 total infusions	7.66	1	0	0	0	1.00e+00	Uros
Intermittent access day 15 total infusions	8.92	1	0	0	0	1.00e+00	Uros
Intermittent access terminal intake (last 3 days)	10	1	0	0	0	1.00e+00	Uros
Intermittent access total infusions	9.54	2	0	0	1	4.29e-03	Uros Adam12
Intermittent access day 1 locomotion	14.59	2	0	0	1	1.50e-03	Uros Adam12
Intermittent access day 15 total locomotion	13.61	2	0	0	1	3.44e-04	Uros Adam12
Intermittent access total locomotion	15.87	2	0	0	1	2.40e-04	Uros Adam12
Lifetime Intake	11.67	2	0	0	1	2.17e-03	Uros Adam12
Progressive ratio test 1 active lever presses	7.8	2	0	0	0	1.00e+00	Uros Adam12
Progressive ratio test 1 breakpoint	7.75	2	0	0	0	1.00e+00	Uros Adam12
Progressive ratio test 2 active lever presses	12.98	2	0	0	1	9.28e-04	Uros Adam12
Progressive ratio test 2 breakpoint	10.94	2	0	0	1	9.75e-04	Uros Adam12
Progressive ratio test 2 inactive lever presses	6.61	2	0	0	0	1.00e+00	Uros Adam12
Total sessions with >9 infusions	10.43	2	0	0	1	2.75e-05	Uros Adam12
Short access day 1 total inactive lever presses	6.51	1	0	0	0	1.00e+00	Uros
Short access day 1 total infusions	10.25	2	0	0	1	6.34e-04	Uros Adam12
Short access day 10 total infusions	8.35	1	0	0	0	1.00e+00	Uros
Short access total infusions	10.05	2	0	0	1	1.52e-04	Uros Adam12
Short access day 1 locomotion	16.24	2	0	0	1	3.81e-04	Uros Adam12
Short access day 10 total locomotion	12.31	1	0	0	0	1.00e+00	Uros
Short access total locomotion	20.79	2	0	0	1	4.55e-04	Uros Adam12
One hour access (shock baseline)	7.09	2	0	0	1	4.62e-03	Uros Adam12
Condit. Reinf. active minus inactive responses	5.88	1	0	0	0	1.00e+00	Adam12
Bone surface	3.94	2	0	0	0	1.00e+00	Uros Adam12
Bone volume	4.16	2	0	0	0	1.00e+00	Uros Adam12
Bone: cortical area	5.43	1	0	0	0	1.00e+00	Uros
Bone: cortical thickness	4.35	1	0	0	0	1.00e+00	Uros
Bone: maximum diameter	4.65	1	0	0	0	1.00e+00	Uros
Bone: periosteal perimeter	4.68	1	0	0	0	1.00e+00	Uros
Distance traveled before self-admin	15.55	1	0	0	0	1.00e+00	Uros
Distance traveled after self-admin	6.29	2	0	0	0	1.00e+00	Uros Adam12
Time in open arm before self-admin	8.94	1	0	0	0	1.00e+00	Adam12
Ambulatory time before self-admin	12.08	1	0	0	0	1.00e+00	Uros
Ambulatory time after self-admin	7.04	2	0	0	1	1.51e-03	Uros Adam12
Locomotion in novel chamber	5.47	1	0	0	0	1.00e+00	Uros
Zn content in liver	8.43	1	0	0	0	1.00e+00	Uros

Associations by panel

Tissue	RNA modality	# hits	% hits/tests	Avg chisq
Adipose	alternative polyA	0	0	1.16
Adipose	alternative TSS	0	0	1.09
Adipose	gene expression	2	0	1.21
Adipose	isoform ratio	0	0	1.18
Adipose	intron excision ratio	0	0	1.14
Adipose	mRNA stability	0	0	1.21
BLA	alternative polyA	0	0	1.17
BLA	alternative TSS	0	0	1.18
BLA	gene expression	0	0	1.23
BLA	isoform ratio	0	0	1.27
BLA	intron excision ratio	0	0	1.14
BLA	mRNA stability	1	0	1.25
Brain	alternative polyA	0	0	1.14
Brain	alternative TSS	0	0	1.13
Brain	gene expression	0	0	1.21
Brain	isoform ratio	0	0	1.19
Brain	intron excision ratio	0	0	1.16
Brain	mRNA stability	0	0	1.18
Eye	alternative polyA	0	0	1.37
Eye	alternative TSS	0	0	1.01
Eye	gene expression	1	0.1	1.24
Eye	isoform ratio	0	0	1.28
Eye	intron excision ratio	0	0	1.09
Eye	mRNA stability	0	0	1.26
IL	alternative polyA	0	0	1.16
IL	alternative TSS	0	0	1.52
IL	gene expression	0	0	1.23
IL	isoform ratio	0	0	1.18
IL	intron excision ratio	0	0	1.13
IL	mRNA stability	0	0	1.27
LHb	alternative polyA	0	0	1.11
LHb	alternative TSS	0	0	1.28
LHb	gene expression	0	0	1.23
LHb	isoform ratio	0	0	1.24
LHb	intron excision ratio	0	0	1.13
LHb	mRNA stability	0	0	1.32
Liver	alternative polyA	0	0	1.11
Liver	alternative TSS	0	0	1.14
Liver	gene expression	0	0	1.19
Liver	isoform ratio	0	0	1.16
Liver	intron excision ratio	0	0	1.18
Liver	mRNA stability	0	0	1.17
NAcc	alternative polyA	0	0	1.19
NAcc	alternative TSS	0	0	1.3
NAcc	gene expression	0	0	1.24
NAcc	isoform ratio	0	0	1.24
NAcc	intron excision ratio	0	0	1.12
NAcc	mRNA stability	0	0	1.31
OFC	alternative polyA	0	0	1.15
OFC	alternative TSS	0	0	1.5
OFC	gene expression	0	0	1.31
OFC	isoform ratio	0	0	1.19
OFC	intron excision ratio	0	0	1.27
OFC	mRNA stability	0	0	1.32
PL	alternative polyA	0	0	1.17
PL	alternative TSS	0	0	1.22
PL	gene expression	0	0	1.25
PL	isoform ratio	0	0	1.24
PL	intron excision ratio	0	0	1.15
PL	mRNA stability	0	0	1.29